ENTA
HealthcareEnanta Pharmaceuticals, Inc.
$13.91
$-0.51 (-3.54%)
Jan 5, 2026
Price History (1Y)
Analysis
Enanta Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $401.34 million and approximately 120 employees. The company's financial health is characterized by low profitability, with gross margin at 100%, but operating margin at -121.6% and profit margin at -125.4%. Returns on equity and assets are also negative, standing at -84.6% and -16.2%, respectively. The balance sheet shows a debt-to-equity ratio of 310.67, indicating significant indebtedness, while cash reserves amount to $188.86 million. The company's valuation is marked by a forward P/E ratio of -5.56, suggesting a significant disconnect from earnings growth expectations. Revenue growth has been modest at 3.5% year-over-year, with revenue standing at $65.32 million in the trailing twelve months. The price-to-book ratio is 4.60, and the price-to-sales ratio is 6.14.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $401.34M
- P/E Ratio
- N/A
- 52-Week High
- $17.15
- 52-Week Low
- $4.09
- Avg Volume
- 398.11K
- Beta
- 0.96
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 120